TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
TriLink BioTechnologies, Inc. has announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor® Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor® XT-8 System for Warfarin sensitivity.
As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor® detection systems.
"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor® products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.
"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.
As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor® detection systems.
"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor® products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.
"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.
